Dana Farber Cancer Institute, Boston, Massachusetts, USA.
MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
J Infect Dis. 2020 Nov 13;222(12):1955-1959. doi: 10.1093/infdis/jiaa579.
SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, which is especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts, by BioMedomics SARS-CoV-2 combined IgM-IgG point-of-care lateral flow immunoassay. The seroprevalence was 31.5% (17.5% IgM+IgG+, 9.0% IgM+IgG-, and 5.0% IgM-IgG+). Of the 200 participants, 50.5% reported no symptoms in the preceding 4 weeks, of which 24.8% (25/101) were seropositive, and 60% of these were IgM+IgG-. These data are the highest seroprevalence rates observed to date and highlight the significant burden of asymptomatic infection.
SARS-CoV-2 抗体检测可定量确定疾病流行率，这在高危社区尤为重要。我们通过 BioMedomics SARS-CoV-2 联合 IgM-IgG 即时侧向流动免疫分析，对马萨诸塞州 COVID-19 疫情中心切尔西的 200 名目前无症状的居民进行了匿名便利抽样。血清阳性率为 31.5%（17.5% IgM+IgG+，9.0% IgM+IgG-，5.0% IgM-IgG+）。在 200 名参与者中，50.5%报告在过去 4 周内没有症状，其中 24.8%（25/101）血清阳性，其中 60%为 IgM+IgG-。这些数据是迄今为止观察到的最高血清阳性率，突出了无症状感染的巨大负担。
